Last reviewed · How we verify

[18F]Florbetapir PET imaging

Institute for Neurodegenerative Disorders · FDA-approved active Small molecule

[18F]Florbetapir is a positron emission tomography (PET) imaging agent that binds to amyloid-beta plaques in the brain to visualize amyloid pathology.

[18F]Florbetapir is a positron emission tomography (PET) imaging agent that binds to amyloid-beta plaques in the brain to visualize amyloid pathology. Used for Positron emission tomography imaging of amyloid pathology in patients with cognitive impairment to assess for Alzheimer's disease pathology, Research and clinical assessment of amyloid-beta burden in neurodegenerative disease.

At a glance

Generic name[18F]Florbetapir PET imaging
Also known asAmyvid
SponsorInstitute for Neurodegenerative Disorders
Drug classPET imaging agent
TargetAmyloid-beta (Aβ) fibrils
ModalitySmall molecule
Therapeutic areaNeurology
PhaseFDA-approved

Mechanism of action

[18F]Florbetapir is a fluorine-18 labeled tracer that crosses the blood-brain barrier and selectively binds to fibrillar amyloid-beta aggregates in the brain. The radioactive fluorine-18 isotope emits positrons that are detected by PET imaging, allowing quantitative and qualitative assessment of amyloid burden. This enables early detection and monitoring of amyloid pathology in neurodegenerative diseases, particularly Alzheimer's disease.

Approved indications

Common side effects

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: